High-Risk Acute Myeloid Leukemia: A Pediatric Prospective.
Fabiana CacaceRossella IulaDanilo De NovellisValeria CaprioliMaria Rosaria D'AmicoGiuseppina De SimoneRosanna CuccurulloWilliam G WierdaKris Michael MahadeoGiuseppe MennaFrancesco Paolo TambaroPublished in: Biomedicines (2022)
Pediatric acute myeloid leukemia is a clonal disorder characterized by malignant transformation of the hematopoietic stem cell. The incidence and the outcome remain inferior when compared to pediatric ALL, although prognosis has improved in the last decades, with 80% overall survival rate reported in some studies. The standard therapeutic approach is a combined cytarabine and anthracycline-based regimen followed by consolidation with allogeneic stem cell transplantation (allo-SCT) for high-risk AML and allo-SCT for non-high-risk patients only in second complete remission after relapse. In the last decade, several drugs have been used in clinical trials to improve outcomes in pediatric AML treatment.
Keyphrases
- acute myeloid leukemia
- stem cell transplantation
- hematopoietic stem cell
- high dose
- allogeneic hematopoietic stem cell transplantation
- clinical trial
- end stage renal disease
- chronic kidney disease
- newly diagnosed
- ejection fraction
- prognostic factors
- randomized controlled trial
- bone marrow
- risk factors
- free survival
- weight loss
- rheumatoid arthritis
- study protocol